Rechallenge of camrelizumab in non-small-cell lung cancer patients treated previously with camrelizumab and microwave ablation

Wei, ZG; Yang, X; Ye, X

Ye, X (corresponding author), Shandong First Med Univ, Affiliated Hosp 1, Dept Oncol, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.; Ye, X (corresponding author), Shandong Prov Qianfoshan Hosp, Shandong Lung Canc Inst, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020; 16 (5): 1191

Abstract

Camrelizumab is a programmed death receptor-1 inhibitor originally developed in China for the treatment of refractory lymphoma. It has also been effec......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索